MET and non-small cell lung carcinoma: MET amplification has been reported in 5–26% of patients with non-small-cell lung cancer (NSCLC) after resistance to epidermal growth factor receptor (EGFR) inhibitor [2–6], with MET exon 14 skipping mutation in approximately 3% of NSCLC [7–9], and c-MET overexpression in about 35–72% of NSCLC [10, 11].